Comparative Pharmacology
Head-to-head clinical analysis: CEPHALOTHIN SODIUM W DEXTROSE IN PLASTIC CONTAINER versus KAFOCIN.
Head-to-head clinical analysis: CEPHALOTHIN SODIUM W DEXTROSE IN PLASTIC CONTAINER versus KAFOCIN.
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER vs KAFOCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalothin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has bactericidal activity against susceptible gram-positive and some gram-negative bacteria.
KAFOCIN (cefepime/enmetazobactam) is a combination of a fourth-generation cephalosporin (cefepime) and a β-lactamase inhibitor (enmetazobactam). Enmetazobactam inhibits extended-spectrum β-lactamases (ESBLs) and other class A β-lactamases, restoring cefepime's activity against β-lactamase-producing bacteria. Cefepime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
1-2 g IV every 4-6 hours; maximum 12 g/day.
1 g IV every 8 hours.
None Documented
None Documented
30-60 minutes in normal renal function; prolonged to 2-8 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life: 4.5-6.5 hours (increased to 12-18 hours in severe renal impairment; CrCl <30 mL/min).
Primarily renal (60-70% unchanged) via glomerular filtration and tubular secretion; minor biliary (5-10%) and fecal (<1%) elimination.
Renal: 60-80% unchanged; biliary/fecal: 15-30% as metabolites; total clearance ~120 mL/min.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic